Bruera et al. BMC Cancer 2010, 10:567 http://www.biomedcentral.com/1471-2407/10/567 Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 24. Kaplan EL, Meier P: Nonparametric estimation of incomplete observations. J am Stat Assoc 1958, 53:457-481. 25. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10. 26. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC: Accelereted titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997, 89(15):1138-47. 27. Masi G, Salvatore L, Fornaro L, Vasile E, Baldi GG, Stasi I, Ciarlo A, Tuzi A, Andreuccetti M, Falcone A: Bevacizumab (BV) in combination with FOLFOXIRI (Irinotecan, Oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): update results of a phase II G.O.N.O. trial. EJC Supplements 2009, 17(2), (suppl; poster 6081). 28. Ficorella C, Morelli MF, Ricevuto E, Cannita K, Porzio G, Baldi PL, Cianci G, Di Rocco ZC, Natoli C, Tinari N, De Galitiis F, Calista F, Marchetti P: Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/ docetaxel regimen in metastatic breast cancer: a dose-finding study. Br J Cancer 2004, 91:618-20. 29. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 351:1408-17. 30. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schch G, Stroh C, Loos AH, Zubel A, Koralewski P: Fluorouracil, Leucoverin, and Oxaliplatin with or without Cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671. 31. Douillard J, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel ME, Humblet Y, Cunningham D, Wolf M, Gansert JL: Randomized phase 3 study of Panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. EJC Supplements 2009, 17:3, (Suppl; abstact 10LBA). 32. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H: Association of k-ras, b- raf, and p53 status with the treatment effect of Bevacizumab. J Natl Cancer Inst 2005, 97(13):981-9. 33. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Kohne CH: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with Cetuximab: the CELIM randomized phase 2 trial. Lancet Oncol 2009. 34. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P: Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000, 356:373-8. 35. Falcone A, Loupakis F, Cupini S, Cortesi E, Buonadonna A, Tomasello G, Banzi M, Ronzoni M, Zaniboni A, Masi G: FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO). J Clin Oncol 2010, 28:15s, (suppl; abstr 3543). Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/10/567/prepub doi:10.1186/1471-2407-10-567 Cite this article as: Bruera et al.: “Poker” association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/ FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer 2010 10:567. Page 10 of 10 Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit